Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Mustang Bio, Inc. announced the first data from the indolent lymphoma cohort of the Company?s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted,...
-Today at 08:00 am- MarketScreener

Related Keywords

Mazyar Shadman ,Fred Hutch ,University Of Washington ,Fred Hutchinson Cancer Center Hutch ,Safety Review Committee ,Mustang Bio Inc ,International Workshop ,Drug Administration ,Mustang Bio ,Fred Hutchinson Cancer Center ,Study Chair ,Associate Professor ,Fred Hutch Sponsored ,Markets ,